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Abstract. Some observational studies have shown that only a small number of diabetic patients achieve optimum control of 
glycaemia and cardiovascular risk factors. The aim of this study was to analyze whether patients with type 2 diabetes 
mellitus treated in primary care achieve adequate control of glycemic levels and cardiovascular risk factors. This was a 
retrospective, record-based, cross-sectional study that included eligible patients from 35 to 90 years old with type 2 diabetes 
mellitus treated in Primary Health Care Center in Podgorica. We investigated electronic records of 531 diabetic patients. 
The observed prevalence of type 2 diabetes mellitus among individuals between ages 35 and 90 years, was 11,84 %. Half of 
the patients were female. The mean age was 65,88±9,86 years. The mean value of HbA1c was 7,56±1,71. Fifty-nine percents 
of patients achieved optimal levels of HbA1c ≤ 7 %. Also, more than half of patients achieved target levels of blood pressure 
while 27.9% achieved LDL ≤ 2.6 mmol/L. Fifty percent of patients were non-smokers and 45.1 % were obese. Among 
patients on primary prevention only 5.7 % had met all target levels while on secondary prevention that number was even 
smaller 3.7 %. Our study showed that control of HbA1c and blood pressure was similar to other studies but reaching target 
levels of LDL was challenging for our patients. Further analysis are needed in order to discover the reasons for poor 
control of certain CVRF and to develop strategies for its optimal management. 
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Introduction 

 
Diabetes mellitus is a serious, chronic disease with an 
overall estimated prevalence of 8.5 % in Europe [1]. 
More than 85% of diabetic patients suffer from type 2 
diabetes mellitus (T2DM) which usually occurs later in 
life [2]. In 50 % of cases T2DM remains undiagnosed 
and untreated for some period of time leading to serious 
chronic complications at the time of diagnosis [3].  
Cardiovascular disease (CVD) is one of the most 
important complications in diabetic patients that reduces 
the quality of life and causes premature death. Several 
studies have shown that the risk of developing CVD in 
diabetic patients is 2 to 3 times higher than in patients 
with normal blood glucose levels [4]. CVD is also the 
most prevalent cause of death in diabetic patients mostly 
due to an increased risk of stroke and myocardial in-
farction [5]. This represents a major public health bur-
den, so prevention and the adequate treatment of this 
disease is a priority for health systems.  
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The existence of national and international guide-
lines for the management of the patients with diabetes 
has eased the care for these patients and set the stand-
ards for their treatment. In 2017 American diabetes 
association (ADA) has issued the guidelines in which 
special emphasis is placed on the field of work of family 
physicians. They should have one of the most important 
roles in adequate caring for diabetic patients because 
adequate metabolic control and control of cardiovascu-
lar risk factors (CVRF) can prevent or slow down CVD 
in these patients [6]. Unfortunately, some observational 
studies have shown that there has been a discrepancy 
between official recommendations and everyday prac-
tice, and that only 7-14% of patients with diabetes 
achieve optimum control of CVRF [7,8]. 
The aim of this study was to analyze whether pa-
tients with T2DM treated in Primary Health Care Center 
in Podgorica achieve adequate control of glycemic lev-
els and CVRF. 
Subjects and Methods  
This was a record-based cross-sectional study that included 
eligible patients with T2DM treated in Primary Health 
Care Center in Podgorica which is the main primary health 
care provider in Montenegro. According to the data that 
researchers got from National Health Insurance Fund, this 
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Primary Health Care Center operates with 119 444 
insurance covered citizens aged 35 to 90 years and 14 144 
of them have T2DM. They are all registered with a general 
practitioner/family doctor. We analyzed 531 electronic 
records of randomly selected patients who have been 
diagnosed with T2DM (International Classification of 
Diseases 10 [ICD-10] codes E11 and E14) before January 
1
 
2016. For every patient we collected following data that 
have been recorded until the end of March 2017: age; sex; 
time since diagnosis; the presence of: retinopathy (ICD-10 
codes E11.3 and H36.0); neuropathy (ICD-10 code G63.2); 
nephropathy (ICD code E11.21 or estimated glomerular 
filtration rate [GFR] with the MDRD [modification of diet 
in renal disease] formula [9] based on the most recent 
serum creatinine level recorded over the previous 15 
months); coronary artery disease (ICD-10 codes I20, I21, 
I22, I23 and I24); stroke (ICD-10 codes I63, I64, G45 and 
G46), peripheral arterial vessel diseases (ICD-10 code 
I73.9) and chronic heart failure (ICD-10 code I50). We 
also collected data about glycemic control (the most 
recently recorded values of glycosylated hemoglobin 
[HbA1c] over the previous 15 months) and control of the 
CVRF - the most recently reported body mass index (BMI) 
over the previous 36 months; mean values of systolic 
(SBP) and diastolic blood pressure (DBP) over the 
previous 12 months; smoking status; the most recently 
recorded levels of total cholesterol (TC), triglyceride (TG), 
low-density lipoprotein (LDL), and high-density 
lipoprotein (HDL) over the previous 12 months. 
In order to asses whether they have achieved control of 
glycemic levels and CVRF we used current ADA 
guidelines and European guidelines on cardiovascular 
disease prevention [6,10]. Target levels for glycemic 
control was HbA1c ≤ 7 % and for CVRF: BP ≤ 140/85, 
TC ≤ 5,0 mmol/L, TG ≤ 1,7, HDL ≥ 1,0 mmol/L for men 
and ≥ 1,2 mmol/L for women, LDL ≤ 2,6 mmol/L for 
primary prevention and ≤ 1,8 mmol/L for secondary 
prevention. 
The approval of the local Ethics Committee was 
obtained.  
Statistical analysis 
Statistical version R 2.15.3 Software (R Foundation for 
Statistical Computing, Vienna, Austria) was used to 
perform the statistical analysis [11]. All data are pre-
sented as the arithmetic mean ± standard deviation or as 
absolute and relative numbers. We used Chi square test 
for comparison of categorical data according to sex. 
Continuous variables were compared with t test and 
Mann-Whitney test. The zero hypothesis was tested 
with a significance threshold p<0.05. 
Results 
The prevalence of T2DM among individuals between 
ages 35 and 90 years, was 11,84 %. Out of 531 patients 
whose records we investigated 50.5 % were female. The 
mean age of the patients was 65,88±9,86 years. The 
majority of them were between 60 and 69 years old. 
Table 1 shows clinical and laboratory characteristics of 
the study population. The mean value of HbA1c was 
7,56±1,71 and there was no significant difference be-
tween men and women (p=0,445). 
Women had higher levels of SBP compared to men 
(p=0.003). Smoking categories differed by gender 
(p<0.001), in the female population non-smokers were 
dominant. Women also had significantly higher levels of 
TC (p<0,001) as well as levels of HDL and LDL (p=0.010; 
p=0.013). 
Table 1 Clinical and laboratory characteristic of the study population 
Characteristics (n, %) Total 
(n=531) 
Men 
(n=263) 
Women 
(n=268) 
p 
Age (years) † 65.88±9.86 64.79±10.27 66.95±9.41 0.012
1 
Age group    
35-39  5 (0.9) 3(1.1) 2(0.7) 0.662
2 
40-49  25(4.7) 16(6.1) 9(3.4)  
50-59 93(17.6) 53 (20.2) 40(15.0)  
60-69 222(42.0) 100(42.0) 112(41.9)  
70-79 139(26.3) 57(21.8) 82(30.7)  
80-89 45(8.5) 23(8.8) 22(8.2)  
Diabetes duration (≥8 years) 272(52.0) 127(49.0) 145(54.9) 0.421
2
 
HbA1c
 
(%)
* 
7.56±1.71 7.53±1.70 7.59±1,72 0.445
1 
Hypertension  456(85.9) 219(83.3) 237(88.4) 0.088
1 
Systolic blood pressure (mmHg)† 142.03±18.77 139.25±16.96 144.87±20.11 0.003
1
 
Diastolic blood pressure (mmHg)† 84.23±9.51 83.88±9.26 84.59±9.78 0.457
1
 
Smokers  87(32.8) 48(36.6) 39(29.1) 0.250
2 
Ex-smokers  45(17.0) 34(26.0) 11(8.2) <0.001
2
 
Body mass index (kg/m2) † 29.67±5.57 29.11±5.17 30.22±5.90 0.163
3
 
Total cholesterol (µmol/L) † 5.60±1.46 5.29±1.21 5.89±1.62 <0.001
3 
Triglycerides (mmol/L) † 2.28±1.36 2.36±1.37 2.21±1.34 0.230
3 
HDL-cholesterol (mmol/L) † 1.20±0.46 1.14±0.44 1.27±0.47 0.010
3 
LDL-cholesterol (mmol/L) † 3.29±1.26 3.09±1.08 3.48±1.38 0.013
3 
1
t test, 
2
 Chi-squared test, 
3
 Mann-Whitney test, † Mean± standard deviation, *Glycated haemoglobin. 
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Prevalence of micro and macroangiopathic compli-
cations is shown in Table 2. There were no significant 
differences in the prevalence of neuropathy, retinopathy 
and nephropathy between men and women (p=1.000; 
p=0,948; p=0.842) assessed by ICD code records. Tak-
ing into account levels of serum creatinine, number of 
patients with GFR between 30 and 89 mL/min is 60.8 
%. Almost one third of patients had coronary artery 
disease and 18.1 % had heart attack or stroke. Heart 
attack was more frequently observed in male patients 
while there was no difference between men and women 
regarding stroke (p=0.046, p=0.455). Researchers got 
data also from National Health Insurance Fund about 
number of patients with history of acute myocardial 
infraction. Out of 14 144 patients 1629 had heart attack 
which is 11.52 % prevalence rate and in concordance 
with prevalence rate from our study sample (11.4 %). 
Table 3 shows results of achieved treatment goals 
regarding glucoregulation and control of CVRF. Fifty-
nine percent of patients achieved optimal levels of 
HbA1c (≤ 7 %). Target levels of SBP≤140 mmHg were 
more frequently attained by men (p=0.038), while there 
was not significant difference in attaining target 
DBP≤85 mmHg between men and women (p=0.646). 
Obesity was more frequent among women (p=0.025). 
Significant difference between men and women in 
achieving target lipid levels was seen only in achieving 
LDL≤1.8 mmol/L which was more frequently observed 
in male population (p=0.039). In patients on primary 
prevention only 5.7 % had met target levels of 
HbA1c≤7 %, BP≤140/85 mmHg and LDL≤2.6 mmol/L 
while on secondary prevention (HbA1c≤7 %, 
BP≤140/85 mmHg, LDL≤1.8 mmol/L) that number was 
even smaller 3.7 %. 
Table 2 Prevalence of diabetes-related micro- and macroangiopathic complications, as assessed by ICD code records 
and laboratory data 
Characteristics 
(n,%) 
Total 
(n=531) 
Men 
(n=263) 
Women 
(n=268) 
p
1 
Retinopathy 103 (19.6) 52 (19.9) 51 (19.3) 0.948
 
Neuropathy 171 (32.4) 85 (32.4) 86 (32.5) 1.000
 
Nephropathy 31 (5.8) 15 (5.7) 16 (5.8) 0.842
 
Creatinine µmol/L† 83.61±35.94 88.63±33.66 78.09±37.63 <0.001
2 
GFR
3
 (mL/min/1.73m
2
)† 76.91±21.21 79.17±19.93 74.43±22.34 0.137
2 
GFR < 30 10 (3.2) 3 (1.8) 7 (4.6) 0.213 
30<GFR<60 64 (20.4) 27 (16.6) 37 (24.7) 0.263 
GFR > 90 124 (39.2) 69 (41.6) 55 (36.7) 0.120 
Coronary artery disease 158 (30.3) 79 (30.5) 79 (30.0) 0.887 
Heart attack 59 (11.4) 37 (14.4) 22 (8.4) 0.046 
Heart attack with revascularisation 34 (6.4) 22 (8.4) 12 (4.8) 0.098 
Revascularisation without heart attack 25 (4.7) 9 (3.4) 16 (6.0) 0.237 
Stroke 35 (6.7) 20 (7.7) 15 (5.7) 0.455 
Peripheral artery disease 67 (12.8) 37 (14.3) 30 (11.4) 0.394 
Chronic heart failure 50 (9.6) 26 (10.0) 24 (9.2) 0.848 
At least one complication 322 (60.6) 163 (62.0) 159 (59.3) 0.592 
1
 Chi-squared test, 
2
 Mann-Whitney test, † Mean ± standard deviation, 3 Glomerular filtration rate. 
Table 3 Results of achieved treatment goals regarding glucoregulation and control of CVRF. 
Characteristics† Total Men Women p
1 
HbA1c≤7% * 314 (59.1) 159(60.5) 155(57.8) 0.599 
Systolic blood pressure ≤ 140 mmHg 172(57.6) 129 (62.9) 105(52.5) 0.038
 
Diastolic blood pressure ≤ 85 mmHg 258 (62.2) 133(64.9) 125(62.2) 0.646
 
Body mass index ≤ 30 kg/m
2 
124 (54,9) 67 (63,2) 57 (47,5) 0.025
 
Non-smokers (%) 133 (50.2) 49 (37.4) 84 (62.7) <0.001 
Total cholesterol ≤ 5.0 µmol/L 154 (29.0) 86 (32.7) 68 (25.4) 0.078
 
Triglycerides ≤ 1.7 mmol/L 162 (30.5) 77(29.3) 85(31.7) 0.606 
HDL-cholesterol ≥ 1 ≥1,2 mmol/L 121 (38.0) 58 (37.7) 63 (38.2)* 0.903
 
LDL-cholesterol < 1.8 mmol/L (n=330) 24(7.3) 17(10.6) 7(4.1) 0.039
 
LDL-cholesterol < 2.6 mmol/L  92(27.9) 49(53.3) 43(46.7) 0.402
 
Primary prevention: HbA1c≤7 %, blood pressure ≤ 
140/85 mmHg, LDL-cholesterol ≤ 2.6 mmol/L 
16 (5.7) 9 (6.5) 7 (4.8) 0.719 
Secondary prevention: HbA1c≤7 %, Blood pressure 
≤ 140/85 mmHg, LDL-cholesterol ≤ 1.8 mmol/L 
5 (3.7) 3 (4.3) 2 (3.1) 0.699 
† count (%), 1 Chi-squared test, * Glycated haemoglobin. 
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Discussion 
According to the report of the International Diabetes 
Federation (IDF) prevalence of diabetes in Montenegro 
for the age group from 20 to 79 years for 2017 is 
12.8 %. Majority of them suffer from T2DM [12]. 
These data place Montenegro among countries with the 
highest prevalence rates in Europe. Our estimated 
prevalence for Podgorica, which is the capital of 
Montenegro, is similar. IDF also reports that diabetes 
prevalence is slightly higher in men than women and 
that age group 65-79 years has the highest prevalence of 
diabetes [12]. We also got similar data for gender and 
age distribution. For half of the patients, disease 
duration could not be estimated precisely because 
electronic records have been introduced since 2009. So, 
we couldn't conclude whether these patients had 
diabetes before 2009 and for how long.  
Electronic records were also a good tool to evaluate 
the percent of diabetic patients with hypertension which 
is the common comorbid condition. Many observational 
studies in Europe have reported similar hypertension rates 
in patients with T2DM (above 75 %) [13]. Hypertension 
in patients with T2DM quadruple CV risk and BP 
measured in office is good predictor of CV morbidity and 
mortality [14,15]. Therefore, ADA recommends that BP 
should be measured in diabetic patients routinely at every 
visit [6]. Mean values of SBP and DBP were slightly 
higher than in a methodologically similar study conducted 
in Spain [7]. Data about BMI and smoking habit were also 
similar like in Spanish study where women had 
significantly higher values of BMI (30.5±5.6 kg/m
2 
women 
vs 28.8±4.3 kg/m
2
 men, p<0.005) and percent of smokers 
was higher among men (24% of men vs 6.0 % of women, 
p<0.005). Mean values of serum lipid levels in our study 
pointed to already known characteristic features of diabetic 
dyslipidemia. This includes high levels of plasma TG, low 
levels of   HDL and increased concentration of LDL [16]. 
Elevated LDL levels represent independent risk factor for 
CVD and major target for its prevention. According to 
meta-analysis that included data from 18 686 diabetic 
patients reduction of LDL per 1 mmol/L resulted in 9 % 
reduction of all cause mortality [17]. Framingham Study 
showed that there was no significant difference in the 
prevalence of elevated LDL levels among diabetic and 
non-diabetic individuals, but other studies showed that 
there was gender difference in diabetic patients regarding 
lipid levels. Russo et al. conducted a large Italian study in 
which diabetic female patients had significantly higher 
levels of TC, HDL and LDL than male patients (p<0.000) 
[18]. Our study showed the same results regarding 
gender-related differences.  
Mean level of HbA1c from our study was also 
comparable to that from other study whose objective 
was to asses prescribing trends and glycemic control in 
patients with T2DM in Catalonia (Spain) during 2007-
2013. In this study, the level of HbA1c was around 
7.2 % with no significant difference across years sug-
gesting that suboptimal glycemic control is a common 
problem [19]. We found that more than a half of our 
patients achieved target levels of HbA1c ≤ 7 % (59.1 %) 
which is a good result compared to other countries where 
the percentage of patients who were not at target varied 
from 26 % in the Netherlands up to 52 % in Turkey [20]. 
Maintaining good glycemic control is very important be-
cause it reduces the risk of developing microvascular and 
macrovascular complications [21].  
In current study, diabetic neuropathy was the most 
commonly reported among microvascular complications, 
while other studies suggest that diabetic retinopathy may 
be the most common microvascular complication with 
prevalence rates ranging from 25-40 % [22,23]. This may 
be explained by an inadequate diagnosis being entered into 
the medical records due to a lack of time, poor doctor-
patient communication, etc. For the same reason, the 
number of patients with reported nephropathy is only 5.8% 
while the number of patients with impaired renal function 
and GFR≤60 ml/min/1.73m2 is 23.7% which is similar to 
the Spanish study (20 %) [7]. Data about macrovascular 
complications were more accurately entered in the medical 
records because the only way for patient to get certain 
medicines was to have adequate diagnosis on the recipe. 
Coronary heart disease was seen in almost one third of 
patients which is higher percentage compared to other 
European studies whose results varied from 11.3 % to 
16.2% [7,24]. One of these studies was big Italian 
multicenter cohort study which enrolled 19 468 patients 
with the aim to estimate the prevalence of coronary heart 
disease. The percentage of patients with heart attack (4.5 % 
of males vs 2.0 % of females, p<0.0001) was lower from 
that observed in our study (14.4 % of males vs 8.4 % of 
females, p=0.046).  
The reason for higher percentage of coronary heart 
disease in our study could be poor control of cardio-
vascular risk factors. We found that glycemic control, 
as well as control of blood pressure did not differ 
much from other studies whereas lipid control was 
harder to achieve. In other studies the number of pa-
tients who achieved target LDL ≤ 1.8 mmol/L varied 
from 37.9 % to 56.2 %, while more than two thirds 
(72.4 %) achieved LDL ≤ 2.6 mmol/L [7,25]. Ac-
cording to National Health and Nutrition Examination 
Survey data from 2007–2010, 18.8 % of diabetic pa-
tients achieved all three goals, while in the Spanish 
study that number was 25 % [7,26]. Disappointingly, a 
small proportion of patients in our study met all three 
goals in primary (5.7 %) and in secondary prevention 
(3.7 %). Some of the reasons for inadequate treatment 
of dyslipidemia could lie with reluctance among phy-
sicians to intensify treatment and with patients not 
complying with the regimen because they have to pay 
for some of the drugs (statins). Concerning the fact 
that LDL plays a central role in the pathogenesis of 
CVD, more aggressive control of this modifiable risk 
factor is needed alone, as well as in combination with 
glycemic and blood pressure control. 
Our study has several strengths and limitations. To 
the best of authors’ knowledge this is the first study 
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that investigates control of glycaemia and CVRF in 
patients with T2DM in Montenegro. Another im-
portant strength derives from inclusion of data from 
primary care database that are closer to the real-life 
than data from randomized clinical trials which have 
strictly controlled conditions. Retrospective design and 
incomplete medical records represent main limitations. 
That is why some of the diabetes-related complications 
(microvascular complications) were underreported and 
its real prevalence could not be estimated.  
Conclusion 
Our study showed high prevalence of T2DM in Mon-
tenegro. This represents significant burden for our health 
care system especially due to the large number of 
complications that diabetes carries with itself. Good control 
of the disease can prevent many of these complications but 
according to a large number of studies this still remains a 
challenge. In the current study the number of diabetic 
patients with coronary heart disease was higher compared 
to other European studies. Also, control of HbA1c and 
blood pressure was similar to other studies but reaching 
target levels of LDL was challenging for our patients. 
Further analyses are needed in order to discover the 
reasons for poor control of certain CVRF and to develop 
strategies for its optimal management. 
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